Souhaitez-vous accéder aux communiqués récents ?

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile

We are pleased with advancements made with our R&D programs and... our lead asset PRP which we are preparing for our world-first, Phase 1b, clinical study

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology

The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP